You might also like
Globus Medical, Inc. is a medical device company headquartered in Audubon, Pennsylvania, specializing in developing and commercializing innovative healthcare solutions to improve the quality of life for patients with musculoskeletal disorders. The company provides a wide range of products, including implantable devices, biologics, surgical instruments, and advanced technologies, to address spinal, orthopedic, and neurosurgical conditions. Globus Medical operates globally, serving hospitals, ambulatory surgery centers, and physicians with a focus on enhancing surgical precision and patient care.
- Musculoskeletal Solutions - Offers implantable devices, biologics, surgical accessories, and neuromonitoring services used in spinal, orthopedic, and neurosurgical procedures. These solutions address a variety of musculoskeletal disorders, from mild pain to severe conditions like paralysis.
- Enabling Technologies - Provides advanced hardware and software systems designed to improve surgical precision, reduce invasiveness, and enhance reproducibility. Includes maintenance and support services for these technologies.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Daniel T. Scavilla ExecutiveBoard | President and Chief Executive Officer | None | Joined GMED in 2015 as CFO, later became Chief Commercial Officer and President, Trauma. Appointed CEO in April 2022. Previously held leadership roles at Johnson & Johnson. | View Report → |
David C. Paul ExecutiveBoard | Chairman of the Board and Executive Chairman | Board Member at Free Flow Medical and Cross Ventures, LLC | Founder of GMED in 2003. Served as CEO until 2017, then transitioned to Executive Chairman. Holds approximately 225 patents. | |
Keith W. Pfeil Executive | Chief Operating Officer and Chief Financial Officer | None | Joined GMED in August 2019 as CFO. Promoted to COO in February 2024. Previously served as EVP and CFO at CSS Industries and worked at Ernst & Young, KPMG, and Arthur Andersen. | |
Kelly G. Huller Executive | Senior Vice President, General Counsel, and Corporate Secretary | Board Member at Chester County Futures | Joined GMED in 2006 as its first in-house counsel. Developed the legal department and oversees global legal functions. Previously a trial attorney at Conrad O'Brien. | |
Ann D. Rhoads Board | Director and Chairperson of the Audit Committee | Board Member at Quidel Corporation, Repare Therapeutics, and iTeos Therapeutics | Joined GMED's board in July 2011. Former CFO of Forty Seven, Inc., Zogenix, Inc., and Premier, Inc. Brings extensive financial and governance expertise. | |
Daniel J. Wolterman Board | Director | CEO of Wolterman Consulting; Board Member at Hyperfine | Joined GMED's board in September 2023. Former Chair of NuVasive's board and CEO of Memorial Hermann Health System. Over 40 years of healthcare industry experience. | |
Daniel T. Lemaitre Board | Director | Chairman and CEO of BlueWind Medical Ltd. | Joined GMED's board in April 2011. Extensive experience in the medical device industry, including leadership roles at CoreValve and Endologix. | |
James R. Tobin Board | Director | Chairman of TransMedics, Board Member at Lyra Therapeutics, Xenter, and Impulse Dynamics | Joined GMED's board in August 2015. Former CEO of Boston Scientific and Biogen. Extensive leadership experience in the medical device and biotech industries. | |
John A. DeFord, Ph.D. Board | Director | Chairman, CEO, and President of Samothrace Medical Innovations; Board Member at Maravai LifeSciences and Nordson Corporation | Joined GMED's board in September 2023. Former CTO of Becton, Dickinson and Company. Extensive R&D leadership in the medical technology sector. | |
Leslie V. Norwalk Board | Director | Strategic Counsel at Epstein Becker & Green; Board Member at Arvinas, ModivCare, and Neurocrine Biosciences | Joined GMED's board in September 2023. Former Acting Administrator for CMS. Extensive experience in healthcare policy and governance. | |
Robert A. Douglas Board | Director | None | Joined GMED's board in December 2019. Former President and COO of ResMed Inc. Brings operational and financial expertise. | |
Stephen T. Zarrilli Board | Director | Board Member at Virtus Investment Partners | Joined GMED's board in May 2019. Former CEO of Safeguard Scientifics and CFO of publicly traded companies. Brings financial and operational expertise. |
-
You've highlighted significant growth in your international spine business, but profitability varies by country. Can you elaborate on the specific challenges you face in achieving consistent profitability internationally, and how you plan to address them, especially in markets with less favorable pricing?
-
Despite delivering strong Q3 results and beating expectations, your guidance for Q4 implies lower sequential growth than in previous years. Are there specific risks or market dynamics contributing to this conservative outlook, and should we anticipate any potential headwinds entering 2025?
-
With competitors recently receiving FDA approval for their spine robots, how do you plan to maintain your competitive edge in the enabling technologies segment, and what impact do you expect this increased competition to have on your robotics sales and market share?
-
Regarding the $150 million in dis-synergies you previously mentioned, can you provide an update on how much has been realized to date and whether you're on track to achieve the anticipated cost savings from the NuVasive integration?
-
Given your ongoing integration of NuVasive, can you elaborate on your appetite for additional M&A activity at this time? How do you plan to balance further acquisitions with the need to fully realize synergies from the current merger without overextending your resources?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
A significant competitor in the medical device industry, which has substantially greater financial, technical, and marketing resources, and may develop alternative treatments, products, or procedures for musculoskeletal disorders that compete directly or indirectly with the company's products. | |
DePuy Synthes | A major competitor in the musculoskeletal device market, with greater financial and operational resources, potentially developing and patenting products earlier or obtaining regulatory approvals faster than the company. |
A significant competitor with established relationships with surgeons and healthcare providers, as well as a large sales and marketing network, which could impact the company's ability to compete effectively. | |
Zimmer Biomet | A competitor with a more expansive portfolio of intellectual property rights and greater experience in obtaining regulatory clearances, posing challenges to the company's market position. |
A competitor in the musculoskeletal device industry, with advantages such as long-term clinical data supporting its products and established distribution networks. | |
A competitor that, along with other smaller public and private companies, may develop alternative treatments or products for musculoskeletal disorders, potentially impacting the company's sales. | |
A competitor in the musculoskeletal device market, which may develop and commercialize products that compete directly or indirectly with the company's offerings. | |
A competitor that could develop alternative treatments or obtain regulatory approvals for competing products more rapidly, affecting the company's ability to commercialize its products. | |
A competitor in the musculoskeletal device space, which, along with other companies, may introduce alternative treatments or procedures that compete with the company's products. |
Recent press releases and 8-K filings for GMED.
- Globus Medical completed its acquisition of Nevro Corp, integrating Nevro as a wholly owned subsidiary and expanding its portfolio in musculoskeletal and neuromodulation technologies.
- The merger involved converting each Nevro share into $5.85 in cash, effectively finalizing the deal on April 3, 2025.
- The strategic acquisition aims to unlock a $2 billion market opportunity and enhance Globus Medical’s market presence.
- Integration progress: The company highlighted its successful merger with NuVasive, which doubled its reach by combining complementary spine technologies and expanded its access to both domestic and international markets.
- Acquisition strategy: Globus Medical announced its intent to acquire Nevro, a move aimed at entering the spinal cord stimulation market—a new, nearly $2 billion market opportunity that supports diversified revenue streams.
- Pipeline and product innovations: The call reviewed new product developments including the DuraPro oscillating drill, enhanced capabilities in the Excelsius robotic system, and the FDA-cleared Reline system, all designed to offer a competitive technical edge.
- Cost synergies and capital allocation: The company underscored its progress in executing cost-saving synergies—reporting over $94 million achieved in the first full year—with plans to reinvest cash flow into R&D, manufacturing, and strategic M&A opportunities.